1Pegram M. Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? [J]. Clin Breast Cancer, 2008,8(Suppl 3):S121-S130.
2Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer [J]. J Clin Oncol, 2009,27(33):5538-5546.
3Zahnow CA. ErbB receptors and their ligands in the breast [J]. Expert Rev Mol Med, 2006,8(23):1-21.
4Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies [J]. J Clin Invest, 2007,117(8):2051-2058.
5Badache A, Goncalves A. The ErbB2 signaling network as a target for breast cancer therapy [J]. J Mammary Gland Biol Neoplasia, 2006,11 ( 1 ): 13 - 25.
6Slamon D J, Godolphin W, Jones LA, et al. Studies of the HER- 2/neu proto-oncogene in human breast and ovarian cancer [J].Science, 1989,244(4905):707-712.
7Slamon D J, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene [J]. Science, 1987,235(4785):177-182.
8Hudis CA. Trastuzumab mechanism of action and use in clinical practice [J]. N Engl J Med, 2007,357(1):39-51.
9Slamon D J, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001,344(11):783-792.
10Blackwell KL, Burstein H J, Sledge GW, et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy [C]. Abstract presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 14-17, 2009; San Antonio, TX.
5Eugenio P. Breast cancer in developing countries[J]. Best Practice &Research Clinical Obstetrics & Gynaecology,2012,26 (2): 283 -290.
6Mellor JD,Cassumbhoy M, Jefford M. Clinical guidance on the peri-operative use of targeted agents in solid tumoroncology [ J ]. AsiaPac J Clin Oncol,2011,7(2) :106-113.
7Walker RA, Day SJ. Transferrin receptor expression in nonmalig-nant and malignant human breast tissue [ J ]. J Pathol, 1986,148(3):217 -224.
8Daniels TR,Delgado T. The transferrin receptor part II:targeted de-livery of therapeutic agents into cancer cells [ J]. Clin Immunol,2006,121(2):159 -176.
9Daniels TR,Delgado T,Rpdrigues JA,et al. The transferrin receptorpart 1 : Biology and targeting with cytotjoxic antibodies for the treat-ment of cancer[ J]. Clin Dev Immunol,2006 ,121 (2) : 144 - 158.
10Fonseca C, Moreira JN, Ciudad CJ, et al. Targeting of stericallystabilised pH - sensitive liposomes to human T - leukaemia cells[J]. Eur J Pharm Biopharm,2005,59(2) :359 - 366.
